Who
Philip Tsai
Chief Technical Officer
Company insider
Files Form 4 as: Chief Technical Officer, Immunome.
In numbers
- Trades disclosed
- 9
- Buys
- 3
- Sells
- 0
- Bought
- $506K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Jun 2024
- Last trade
- 23 Jul 2026
- Last filed
- 27 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —38,250 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,500 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —76,500 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —38,250 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $205K10,000 at $20.49 | filing |
| 29 Jul 2025filed 31 Jul 2025 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,000 at $0.00 | filing |
| 24 Mar 2025filed 25 Mar 2025 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $104K12,300 at $8.42 | filing |
| 21 Nov 2024filed 25 Nov 2024 | IMNM ImmunomeBiotechnology | SEC FORM 4 Bought | $198K21,000 at $9.43 | filing |
| 17 Jun 2024filed 18 Jun 2024 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonIMNM · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Philip Tsai; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.